All News
Filter News
Found 808,679 articles
-
I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S.
9/12/2019
I-Mab Biopharma announced the appointment of Mr. Neil K. Warma as General Manager of I-Mab Biopharma U.S., Limited on September 3rd.
-
Aspen Laser Now Offering 5-Year Warranty on All New Purchases
9/12/2019
Company is the first Class IV Laser Therapy provider to offer such a guarantee
-
Moretsky Cassidy Performs Successful PanOptix Trifocal Lens Implant
9/12/2019
We are proud to announce that Dr. Sanford Moretsky and Dr. Craig Cassidy, of Valley Eye Specialists, were amongst the first select group of eye surgeons nationally to implant the Alcon AcrySof® IQ PanOptix® Trifocal Intraocular Lens, after FDA approval.
-
Inotrem Announces €39 Million Series B Financing to Develop First-In-Class Immunology Therapeutics
9/12/2019
Inotrem S.A. announced a €39 million Series B financing led by Morningside Ventures, joined by Invus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.
-
Imfinzi® (durvalumab) is the First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer
9/12/2019
Data presented at the IASLC 2019 World Conference on Lung Cancer demonstrated the Phase III CASPIAN trial of Imfinzi improved survival with either a cisplatin or carboplatin chemotherapy backbone
-
Northwest Specialty Hospital opens North Idaho's first Bone Health Clinic
9/12/2019
Northwest Specialty Hospital recently opened Northwest Bone Health, an important new medical service that is the first of its kind in North Idaho.
-
RaySearch to Demonstrate Machine Learning Advances at ASTRO
9/12/2019
During 15-17 September, RaySearch will exhibit its latest advances in oncology software at the American Society for Radiation Oncology 2019 annual meeting in Chicago, USA.
-
Healthy.io Raises $60 Million in Series C Funding and Receives FDA Clearance for Smartphone-Based Test to Diagnose Chronic Kidney Disease
9/12/2019
Former Aetna executive Gary Loveman will join Board of Directors
-
Hyundai Hope On Wheels Presents University Of Minnesota Masonic Children's Hospital With $300,000 Hyundai Scholar Hope Grant To Support Pediatric Cancer Research
9/12/2019
The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this September during Childhood Cancer Awareness Month to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research
-
Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting
9/12/2019
Late-Breaking Results Include First Durability Data from Phase 1b Study of KSI-301 in Treatment-Naïve Patients with Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion [12-September-2019] PALO ALTO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeut
-
Massage Envy, #1 Provider of Skincare in the U.S., Announces Strategic Partnership to Help the 50 Million Americans Who Suffer from Acne
9/12/2019
Massage Envy, the nation's #1 provider of massage and skin care services, announced a breakthrough new acne series to be rolled out nationally by early 2020.
-
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
9/12/2019
Ardelyx, Inc. announced that the U.S. Food and Drug Administration has approved IBSRELA®, a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation in adults.
-
Weight Loss Researcher Presents Latest Findings: Shaklee Life Shake™ Preserves Muscle During Weight Loss with Remarkable Results During Weight Loss and Maintenance Phases of Study
9/12/2019
Shaklee Corporation was honored to feature Wayne Westcott, Ph.D. as a keynote speaker at the Science Symposium held as part of its 2019 Global Conference in July.
-
Qfix® Announces FDA 510(k) Clearance of Encompass™ 15 Channel Head Coil for Siemens 3T MRI Systems
9/12/2019
Qfix has received FDA 510 clearance for the Encompass 15-Channel Head Coil, a diagnostic imaging device optimized for use with the Encompass™ MR SRS Immobilization Device.
-
Investment Plan for Europe – Successful launch of Tech Transfer Fund “KHAN-I”
9/12/2019
Khanu Management GmbH, a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG, based in Dortmund, Germany.
-
East Lancashire Hospitals NHS Trust Joins TriNetX to Improve Research Capabilities and Attract More Clinical Trial Opportunities
9/12/2019
East Lancashire Hospitals NHS Trust, a large integrated healthcare organization serving over a half million patients in north west England, has joined the TriNetX global health research network to improve its research intelligence capabilities, bring more research opportunities to its patients, and enhance overall study performance for sponsors.
-
Physicians’ Education Resource® Announces Agenda for 3rd Annual New York Cardio-Endo-Renal Collaborative
9/12/2019
One-day meeting will focus primarily on the strategic and novel approaches to management of integrated cardiometabolic diseases
-
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery
9/12/2019
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules
-
Walgreens to Offer 3 Percent Daily Cash on Apple Card with Apple Pay Purchases
9/12/2019
Starting on Friday, September 13, Walgreens customers will receive 3 percent Daily Cash when they use Apple Card with Apple Pay on eligible purchases, including prescriptions, made in Walgreens and Duane Reade stores, and for purchases made on the Walgreens app and on walgreens.com.
-
Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints
9/12/2019
Celgene Corporation announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.